3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
2
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, T-Cell
1
Lymphoma
1
Leukemia, Myelomonocytic, Acute
1
Leukemia, Monocytic, Acute
1
Leukemia, Megakaryoblastic, Acute
1
Leukemia, Erythroblastic, Acute
1
Leukemia
1
Interventions
Cytarabine
34
Busulfan
17
Cyclophosphamide
16
fludarabine phosphate
15
Peripheral Blood Stem Cell Transplantation
13
Filgrastim
13
Etoposide
13
Idarubicin
12
Mitoxantrone
9
Cyclosporine
9
Antilymphocyte Serum
9
Methotrexate
8
Daunorubicin
8
Whole-Body Irradiation
6
Radiotherapy
6
Tacrolimus
5
Cord Blood Stem Cell Transplantation
5
Clofarabine
5
Mycophenolic Acid
4
Methylprednisolone
4
Melphalan
4
Gemtuzumab
4
Flow Cytometry
4
Arsenic Trioxide
4
aldesleukin
3
Topotecan
3
Imatinib Mesylate
3
Cytogenetic Analysis
3
Cyclosporins
3
Bortezomib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Leukemia, Erythroblastic, Acute
×
BI 6727
×
Clear all
NCT02527174
2017-04-05
VIAC
University of Alberta
Phase 1
Withdrawn